TY - JOUR AU - Martucci, Gennaro AU - Panarello, Giovanna AU - Occhipinti, Giovanna AU - Raffa, Giuseppe AU - Tuzzolino, Fabio AU - Capitanio, Guido AU - Carollo, Tiziana AU - Lino, Giovanni AU - Bertani, Alessandro AU - Vitulo, Patrizio AU - Pilato, Michele AU - Lorusso, Roberto AU - Arcadipane, Antonio PY - 2018 TI - Impact of cannula design on packed red blood cell transfusions: technical advancement to improve outcomes in extracorporeal membrane oxygenation JF - Journal of Thoracic Disease; Vol 10, No 10 (October 26, 2018): Journal of Thoracic Disease Y2 - 2018 KW - N2 - Background: Technological improvement has contributed to making veno-venous extracorporeal membrane oxygenation (VV-ECMO) safer and easier, spreading its use in acute respiratory failure (ARF). Methods: This is a retrospective observational study carried out in the ECMO center at IRCCS-ISMETT, a medical center focused on end-stage organ failure treatment in Italy. We investigated the effect of different cannula designs on the amount of blood product transfused. Eighty-nine consecutive patients affected with ARF on VV-ECMO from 2008 to 2016 were compared according to type of cannulation: older percutaneous cannula (Standard group, 52 patients) and HLS © BIOLINE-coated, but with shorter drainage cannula (BIOLINE group, 37 patients). Results: The two study groups were comparable in terms of baseline characteristics [age, body mass index (BMI), Simplified Acute Physiology Score (SAPS-II), Sequential Organ Failure Assessment (SOFA), Predicting Death For Severe ARDS on VV-ECMO (PRESERVE) score] and ECMO management [median hematocrit (Htc), platelet nadir, antithrombin III (AT III), heparin, activated partial thromboplastin time (APTT)]. In the BIOLINE group, a lower amount of packed red blood cells (pRBC) was transfused considering both total number [4 units, interquartile range (IQR) 1–9 vs . 12 units, IQR 5.5–21; P vs . 193.5, IQR 140.5–254; P Conclusions: More biocompatible and shorter drainage cannula may represent one of the contributing factors to a reduction in transfusions and costs of VV-ECMO in the current ongoing technological improvement in ECMO. UR - https://jtd.amegroups.org/article/view/24506